Galapagos Biotech LTD announces that the National Institute of Health and Clinical Excellence (NICE) has recommended the use of JYSELECA® (filgotinib) for the treatment of adults with moderately to severely active Ulcerative Colitis (UC) when other treatments have not been successful..